The Role of Tyrosine Kinase Inhibitors in Unresectable Hepatocellular Carcinoma - Episode 5

Emerging Therapies in Intermediate-Stage HCC

April 30, 2024

The panelists examine the effectiveness of transarterial chemoembolization (TACE) in treating hepatocellular carcinoma in patients with intermediate-stage disease and discuss the future prospects for these patients.

Video Player is loading.

Current Time 0:00

Duration 0:00

Loaded: 0%

Stream Type LIVE

Remaining Time 0:00

EP. 1: Examining the Role of Liver Function in HCC

EP. 2: HCC Staging: Improving Treatment Strategies

EP. 3: Locoregional Therapies for Intermediate-Stage HCC

EP. 4: HCC Trials: Insights from the LAUNCH, EMERALD-1, and LEAP-012 Trials

Now Viewing

EP. 5: Emerging Therapies in Intermediate-Stage HCC

EP. 6: Updates from IMbrave150, LEAP-002, and HIMALAYA Trials

EP. 7: Comorbidity Considerations for HCC Treatment

EP. 8: The Evolving Landscape of Second-Line Therapies in HCC Management

EP. 9: Additional Second-Line Treatments for HCC

EP. 10: Real-World Evidence on Second-Line Therapy Selection and Outcomes

EP. 11: Pioneering Breakthroughs in HCC Treatment